Sentences with phrase «pimobendan delays»

BUT, we now know from the PROTECT2 study that in Dobermanns with early - stage DCM (i.e. heart enlargement on ultrasound but no symptoms of CHF), treatment with pimobendan delays the onset of CHF by an average of 9 months.

Not exact matches

The EPIC Study showed that administration of pimobendan resulted in a 15 ‑ month delay in time to primary endpoint compared with dogs receiving placebo.

To determine whether chronic oral administration of pimobendan in dogs with evidence of increased heart size secondary to preclinical myxomatous mitral valve disease (MMVD) can delay the onset of clinical signs of congestive heart failure (CHF).1

This is because the recently published EPIC1 study showed that early treatment with pimobendan in MVD Stage B2 dogs will delay the development of symptoms of congestive heart failure (CHF) by an average of 15 months.

The QUEST Study established pimobendan as the new standard of treatment for dogs with congestive heart failure (CHF) caused by MMVD as it extended survival time.2 The veterinary community also sought to answer this question: Can pimobendan also delay the onset of clinical signs of CHF?

The EPIC Study showed that administration of pimobendan resulted in a 15 ‑ month delay in onset of clinical signs of CHF, cardiac ‑ related death, or euthanasia compared with dogs receiving placebo.

This groundbreaking study sought to answer a key question: Can pimobendan — with proven efficacy in treating dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)-- also delay the onset of CHF caused by MMVD?

Recent results from the EPIC Study, however, show that pimobendan, when administered to dogs in stage B2 — before clinical signs of heart failure appear — succeeded in delaying the onset of CHF.

The EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study1 analysed whether long - term administration of pimobendan to dogs with stage B2 myxomatous mitral valve disease (MMVD) and echocardiographic and radiographic evidence of cardiac enlargement will delay onset of clinical signs of congestive heart failure (CHF), cardiac - related death, or euthanasia (composite primary Pimobendan In dogs with Cardiomegaly) Study1 analysed whether long - term administration of pimobendan to dogs with stage B2 myxomatous mitral valve disease (MMVD) and echocardiographic and radiographic evidence of cardiac enlargement will delay onset of clinical signs of congestive heart failure (CHF), cardiac - related death, or euthanasia (composite primary pimobendan to dogs with stage B2 myxomatous mitral valve disease (MMVD) and echocardiographic and radiographic evidence of cardiac enlargement will delay onset of clinical signs of congestive heart failure (CHF), cardiac - related death, or euthanasia (composite primary endpoint).